Published in Viruses on November 15, 2011
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol (2014) 0.96
Hepatitis C virus infection: establishment of chronicity and liver disease progression. EXCLI J (2014) 0.90
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses (2012) 0.88
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol (2015) 0.86
Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus. J Virol (2015) 0.82
Ultradeep pyrosequencing of hepatitis C virus hypervariable region 1 in quasispecies analysis. Biomed Res Int (2013) 0.81
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome. BMC Infect Dis (2014) 0.79
Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses (2012) 0.78
Clinical impact of hepatitis B and C virus envelope glycoproteins. World J Gastroenterol (2013) 0.78
Multiantibody strategies for HIV. Clin Dev Immunol (2013) 0.78
New insight into HCV E1/E2 region of genotype 4a. Virol J (2014) 0.77
Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells. Virology (2015) 0.76
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A (1991) 14.05
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
The global burden of hepatitis C. Liver Int (2009) 8.89
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol (2004) 6.67
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
RNA virus populations as quasispecies. Curr Top Microbiol Immunol (1992) 5.42
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements (2004) 5.19
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 4.47
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol (2004) 4.12
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol (2008) 3.79
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol (1998) 3.77
Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (1992) 3.59
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Basic concepts in RNA virus evolution. FASEB J (1996) 3.35
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol (1994) 3.06
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Transmissible agent in non-A, non-B hepatitis. Lancet (1978) 2.78
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol (1993) 2.74
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol (1999) 2.52
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (1993) 2.36
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol (2010) 2.12
Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl (2006) 2.12
Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem (2010) 2.05
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 2.02
Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol (2009) 2.00
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol (1999) 1.98
Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat (1996) 1.94
Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol (1991) 1.93
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A (2007) 1.89
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology (2006) 1.88
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
On the nature of virus quasispecies. Trends Microbiol (1996) 1.73
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol (2009) 1.72
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology (1996) 1.70
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res (1992) 1.68
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol (2010) 1.64
The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol (2008) 1.63
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Extraordinarily low density of hepatitis C virus estimated by sucrose density gradient centrifugation and the polymerase chain reaction. J Gen Virol (1992) 1.56
Glycosylation of hepatitis C virus envelope proteins. Biochimie (2003) 1.56
Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis (2004) 1.54
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J (2006) 1.52
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol (1998) 1.48
New therapies for hepatitis C virus infection. Clin Infect Dis (2009) 1.46
Adaptive immunity to the hepatitis C virus. Adv Virus Res (2010) 1.43
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
Hepatitis C virus entry into host cells. Cell Mol Life Sci (2008) 1.40
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37
Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology (1993) 1.36
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 1.34
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 1.33
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol (2010) 1.31
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog (2007) 2.98
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53
Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA (2002) 2.20
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology (2006) 1.88
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol (2008) 1.63
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Res (2008) 1.57
Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology (2008) 1.49
Herpes simplex virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 and UL28. J Virol (2003) 1.37
Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol (2009) 1.30
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol (2007) 1.27
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol (2007) 1.24
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology (2008) 1.16
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Analysis of the processing and transmembrane topology of the E2p7 protein of hepatitis C virus. J Gen Virol (2005) 1.12
Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol (2013) 1.11
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One (2009) 1.10
Identification of herpes simplex virus RNAs that interact specifically with regulatory protein ICP27 in vivo. J Biol Chem (2003) 1.09
Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. J Med Virol (2003) 1.08
A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly. J Virol (2009) 1.07
A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res (2009) 1.05
Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int (2005) 1.02
A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol (2008) 1.02
Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells. PLoS One (2011) 1.02
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol (2012) 0.99
Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One (2013) 0.93
Characterization of HCV-like particles produced in a human hepatoma cell line by a recombinant baculovirus. Biochem Biophys Res Commun (2005) 0.91
Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell (2010) 0.90
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol (2010) 0.89
Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA. J Gen Virol (2009) 0.88
Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol (2007) 0.85
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol (2011) 0.85
Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiol (2011) 0.83
Non cell autonomous upregulation of CDKN2 transcription linked to progression of chronic hepatitis C disease. Aging Cell (2013) 0.82
Conserved glycine 33 residue in flexible domain I of hepatitis C virus core protein is critical for virus infectivity. J Virol (2011) 0.81
Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. PLoS One (2007) 0.81
Modeling human liver biology using stem cell-derived hepatocytes. Int J Mol Sci (2013) 0.80
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol (2005) 0.80
Characterisation of bacterially expressed structural protein E2 of hepatitis C virus. Protein Expr Purif (2004) 0.79
Rapid synchronization of hepatitis C virus infection by magnetic adsorption. J Virol Methods (2009) 0.78
Effect of tunicamycin on the biogenesis of hepatitis C virus glycoproteins. Acta Biochim Pol (2010) 0.76
Corrigendum: Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Sci Rep (2016) 0.75